These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25120790)

  • 41. Expression of MAGE genes in renal cell carcinoma.
    Yamanaka K; Miyake H; Hara I; Gohji K; Arakawa S; Kamidono S
    Int J Mol Med; 1998 Jul; 2(1):57-60. PubMed ID: 9854143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma.
    Kienstra MA; Neel HB; Strome SE; Roche P
    Head Neck; 2003 Jun; 25(6):457-63. PubMed ID: 12784237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of MAGE-A12 in oral squamous cell carcinoma.
    Mollaoglu N; Vairaktaris E; Nkenke E; Neukam FW; Ries J
    Dis Markers; 2008; 24(1):27-32. PubMed ID: 18057533
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
    Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS
    Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study.
    Matković B; Juretić A; Spagnoli GC; Separović V; Gamulin M; Separović R; Sarić N; Basić-Koretić M; Novosel I; Kruslin B
    Croat Med J; 2011 Apr; 52(2):171-7. PubMed ID: 21495200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study.
    Forchhammer S; Pop OT; Hahn M; Aebischer V; Seitz CM; Schroeder C; Liebmann A; Abele M; Wild H; Bien E; Kunc M; Schneider DT; Cuk K; Büttel I; Flemmig C; Peters M; Laible M; Brück P; Türeci Ö; Sahin U; Flatz L; Brecht IB
    Virchows Arch; 2024 Aug; 485(2):335-346. PubMed ID: 38890171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
    Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
    Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation.
    Ma X; Fan Y; Gao Y; Zhang Y; Huang Q; Ai Q; Ni D; Chen W; Zhang P; Song E; Wang B; Shi T; Zheng T; Zhang X
    Urol Oncol; 2014 Jan; 32(1):46.e9-17. PubMed ID: 24094887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TGF-β-activated kinase-1: a potential prognostic marker for clear cell renal cell carcinoma.
    Wei C; Lai YQ; Li XX; Ye JX
    Asian Pac J Cancer Prev; 2013; 14(1):315-20. PubMed ID: 23534745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.
    Stoyanoff TR; Rodríguez JP; Todaro JS; Espada JD; Colavita JP; Brandan NC; Torres AM; Aguirre MV
    Tumour Biol; 2016 Oct; 37(10):13581-13593. PubMed ID: 27468719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Downregulation of OCLN and GAS1 in clear cell renal cell carcinoma.
    Conceição AL; Da Silva CT; Badial RM; Valsechi MC; Stuqui B; Gonçalves JD; Jasiulionis MG; De Freitas Calmon M; Rahal P
    Oncol Rep; 2017 Mar; 37(3):1487-1496. PubMed ID: 28184927
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of melanoma-associated antigens in oral squamous cell carcinoma.
    Ries J; Vairaktaris E; Mollaoglu N; Wiltfang J; Neukam FW; Nkenke E
    J Oral Pathol Med; 2008 Feb; 37(2):88-93. PubMed ID: 18197853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The expression of 11 cancer/testis (CT) antigen genes in esophageal carcinoma].
    Liang Z; Sun ZY; Yuan YH; Han Y; Wang Y; Gu J; Zhang LJ
    Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):534-7. PubMed ID: 16438850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RALY RNA binding protein-like reduced expression is associated with poor prognosis in clear cell renal cell carcinoma.
    Cui ZW; Xia Y; Ye YW; Jiang ZM; Wang YD; Wu JT; Sun L; Zhao J; Fa PP; Sun XJ; Gui YT; Cai ZM
    Asian Pac J Cancer Prev; 2012; 13(7):3403-8. PubMed ID: 22994768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
    Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
    Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy.
    Forghanifard MM; Gholamin M; Farshchian M; Moaven O; Memar B; Forghani MN; Dadkhah E; Naseh H; Moghbeli M; Raeisossadati R; Abbaszadegan MR
    Cancer Biol Ther; 2011 Aug; 12(3):191-7. PubMed ID: 21613820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target.
    Zhang QM; He SJ; Shen N; Luo B; Fan R; Fu J; Luo GR; Zhou SF; Xiao SW; Xie XX
    Int J Clin Exp Pathol; 2014; 7(7):3918-27. PubMed ID: 25120768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
    Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
    Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.
    Schrödter S; Braun M; Syring I; Klümper N; Deng M; Schmidt D; Perner S; Müller SC; Ellinger J
    Mol Cancer; 2016 Feb; 15():10. PubMed ID: 26831905
    [TBL] [Abstract][Full Text] [Related]  

  • 60. YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis.
    Cao JJ; Zhao XM; Wang DL; Chen KH; Sheng X; Li WB; Li MC; Liu WJ; He J
    Oncol Rep; 2014 Oct; 32(4):1594-600. PubMed ID: 25175178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.